Two-Drug combo aims to cure chronic hepatitis b

NCT ID NCT06537414

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether giving two experimental drugs in sequence can achieve a functional cure for chronic hepatitis B. Participants are adults with chronic HBV who are already on standard antiviral therapy. They will receive either one of two doses of daplusiran/tomligisiran followed by bepirovirsen, or a placebo, to see if the combination can suppress the virus long-term without ongoing treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daplusiran/Tomligisiran and Bepirovirsen
What this could lead to: If successful, this sequential therapy could offer a functional cure for chronic hepatitis B, allowing patients to stop all treatments while keeping the virus suppressed.
What could go wrong: This is a Phase 2b trial, so the approach is still experimental. It may not achieve sustained viral suppression, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS INFECTION HEPATITIS B

Contacts and locations

Show contact details

Locations

GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

San Jose, California, 95116, United States
GSK Investigational Site

Minneapolis, Minnesota, 55415, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Westmead, New South Wales, 2145, Australia
GSK Investigational Site

Fitzroy, Victoria, 3065, Australia
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Aracaju, 49060-010, Brazil
GSK Investigational Site

Curitiba, 80810-050, Brazil
GSK Investigational Site

Manaus, 69040-000, Brazil
GSK Investigational Site

São Paulo, 05403-000, Brazil
GSK Investigational Site

Calgary, Alberta, T2N 4Z6, Canada
GSK Investigational Site

Ottawa, Ontario, K1H8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2C4, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Beijing, 100050, China
GSK Investigational Site

Chengdu, 610072, China
GSK Investigational Site

Guangzhou, 510630, China
GSK Investigational Site

Shanghai, 200040, China
GSK Investigational Site

Clichy, 92118, France
GSK Investigational Site

Créteil, 94010, France
GSK Investigational Site

Limoges, 87042, France
GSK Investigational Site

Lyon, 69004, France
GSK Investigational Site

Marseille, 13008, France
GSK Investigational Site

Berlin, 10439, Germany
GSK Investigational Site

Berlin, 10787, Germany
GSK Investigational Site

Hanover, 30625, Germany
GSK Investigational Site

Münster, 48149, Germany
GSK Investigational Site

Athens, 10676, Greece
GSK Investigational Site

Athens, 11527, Greece
GSK Investigational Site

Pokfulam, Hong Kong
GSK Investigational Site

Shatin, Hong Kong
GSK Investigational Site

Bergamo, 24127, Italy
GSK Investigational Site

Florence, 50134, Italy
GSK Investigational Site

Milan, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Padova, 35131, Italy
GSK Investigational Site

Pisa, 56124, Italy
GSK Investigational Site

Roma, 00161, Italy
GSK Investigational Site

Chiba, 270-1694, Japan
GSK Investigational Site

Hokkaido, 006-8555, Japan
GSK Investigational Site

Hokkaido, 053-8506, Japan
GSK Investigational Site

Hyōgo, 660-8550, Japan
GSK Investigational Site

Kagawa, 760-8557, Japan
GSK Investigational Site

Kagawa, 761-0793, Japan
GSK Investigational Site

Kumamoto, 860-8556, Japan
GSK Investigational Site

Kumamoto, 862-8655, Japan
GSK Investigational Site

Osaka, 540-0006, Japan
GSK Investigational Site

Osaka, 565-0871, Japan
GSK Investigational Site

Tokyo, 180-8610, Japan
GSK Investigational Site

Yamanashi, 409-3898, Japan
GSK Investigational Site

Auckland, 1023, New Zealand
GSK Investigational Site

Papatoetoe Auckland, 2025, New Zealand
GSK Investigational Site

Singapore, 119074, Singapore
GSK Investigational Site

Singapore, 169608, Singapore
GSK Investigational Site

Johannesburg, 2193, South Africa
GSK Investigational Site

Reiger Park, 1459, South Africa
GSK Investigational Site

Ansan, 15355, South Korea
GSK Investigational Site

Busan, 47392, South Korea
GSK Investigational Site

Pusan, 49241, South Korea
GSK Investigational Site

Seoul, 07061, South Korea
GSK Investigational Site

Seoul, 138-736, South Korea
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

León, 24080, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Salamanca, 37007, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

Kaohsiung City, 807, Taiwan
GSK Investigational Site

Kaohsiung City, 824, Taiwan
GSK Investigational Site

Taichung, 404, Taiwan
GSK Investigational Site

Tau-Yuan, 333, Taiwan
GSK Investigational Site

London, E1 8PR, United Kingdom
GSK Investigational Site

London, SE5 9RS, United Kingdom
GSK Investigational Site

London, SW17 0QT, United Kingdom
GSK Investigational Site

Middlesbrough, TS4 3BW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.